Cargando…
Anticancer osmium complex inhibitors of the HIF-1α and p300 protein-protein interaction
The hypoxia inducible factor (HIF) pathway has been considered to be an attractive anti-cancer target. One strategy to inhibit HIF activity is through the disruption of the HIF-1α–p300 protein-protein interaction. We report herein the identification of an osmium(II) complex as the first metal-based...
Autores principales: | Yang, Chao, Wang, Wanhe, Li, Guo-Dong, Zhong, Hai-Jing, Dong, Zhen-Zhen, Wong, Chun-Yuen, Kwong, Daniel W. J., Ma, Dik-Lung, Leung, Chung-Hang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320473/ https://www.ncbi.nlm.nih.gov/pubmed/28225008 http://dx.doi.org/10.1038/srep42860 |
Ejemplares similares
-
Antagonizing STAT5B dimerization with an osmium complex
por: Liu, Li-Juan, et al.
Publicado: (2016) -
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
por: Cheng, Sha-Sha, et al.
Publicado: (2020) -
A small molecule HIF-1α stabilizer that accelerates diabetic wound healing
por: Li, Guodong, et al.
Publicado: (2021) -
Correction to: The design and development of covalent protein-protein interaction inhibitors for cancer treatment
por: Cheng, Sha-Sha, et al.
Publicado: (2020) -
Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells
por: Cheng, Shasha, et al.
Publicado: (2021)